Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submission

Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing in

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in g

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consens

RMAT designation is intended to help expedite development of new regenerative medicines that have po

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRo

Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens

Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth

Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati

Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co

Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi

Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, w

OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. cont

Study supports favorable safety and tolerability profile and clinically meaningful functional and st

Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus est

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwang

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

With enrollment scheduled to be complete in the first quarter of 2026 the Company remains on track f

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus